semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-80.0,  Asthma This study will enroll parents of children (ages 5-17 years) with asthma and adult patients with asthma (ages 18-80 years) who receive care at one of 4 New York Ciry medical centers (New York Presbyterian Hospital-Columbia campus, New York Presbyterian Hospital-Cornell campus, Harlem Hospital Center, and Jacobi Medical Center) Diagnosis of persistent asthma (as defined by NHLBI guidelines) All participants are new patients to the practice Had never been seen by a specialist physician for asthma care Had never received a written asthma action plan  Co-morbidity with conditions that affect lung function (e.g, congenital or acquired heart disease, neuromuscular disease, sickle cell disease, or chronic lung disease [bronchopulmonary dysplasia, emphysema, or cystic fibrosis])
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Prostate Cancer Prostate cancer patients who were recorded at National Taiwan University Hospital from 1977 to 2002  Patients or their family who refused our contact or were unable to be contacted
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-999.0,  Asthma physician-diagnosed asthma age 6 or older pre-bronchodilator forced expiratory volume (FEV1) of at least 60% of predicted beta-agonist reversibility OR airways hyperreactivity by methacholine challenge Juniper Asthma Control Score of 1.5 or greater if not on daily controller good current health  current or past smoking (greater than 20 pack-years) chronic or current oral steroid therapy pregnancy, lack of effective contraception (when appropriate), lactation
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Asthma COPD age ≥50 years persistent asthma symptoms using short-acting ß-adrenergic agonists medication willingness and ability to keep a daily symptom diary willingness to perform peak flow monitoring health plan membership for at least 6 months use of any combination of ß-agonists and inhaled corticosteroids, theophylline, cromolyn, nedocromil, or ipratropium bromide  unable to provide informed consent not available for duration of study dementia chronic lung disease other than asthma or COPD clinically significant, active disease of the gastrointestinal, cardiovascular, hepatic, neurological, renal, genitourinary, or hematologic systems a major surgical procedure within the four weeks prior to the baseline visit previous adverse reaction to montelukast unresolved symptoms of an upper respiratory tract infection within three weeks prior to baseline initiation of immunotherapy within six months before enrollment or the dose of immunotherapy was expected to change over the course of the study inability to adequately perform spirometry
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 4.0-15.0,  Asthma Main History of persistent bronchial asthma for at least 6 months FEV1 50-90% of predicted Main  Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function Respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study History of life-threatening asthma Premature birth Current smoking Smoking history with either equal or more than 10 pack-years Pregnancy Intention to become pregnant during the course of the study Breast feeding
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Asthma The final diagnosis of severe asthma will be made according to the screening steps we have set up. The definition will require the presence of one or both major (treatment with continuous or near continuous oral corticosteroids and/or requirement for treatment with high dose inhaled steroids) and two minor criteria. Patients who do not fit the of severe asthma will not be entered into the study. Age 18-60; both sexes. For the investigation of fiberoptic bronchoscopy, other additional will be imposed: 1. Post-bronchodilator FEV1 greater than 40% on the day of the bronchoscopy 2. No evidence of an exacerbation of asthma within the past 4 weeks. 3. Ability to cooperate with procedures 4. Ability to give consent 5. Current smokers, and ex-smokers with greater than 10 pack years history of smoking  Pregnancy or unreliable contraceptive measures in child-bearing woman. he bronchoscopist has determined the subject is clinically appropriate for bronchoscopy -
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Asthma History of asthma for at least one year,confirmed objectively. 2. New or previously reviewed patients where the minimal treatment requirements have not been established within the last six months  Smokers or ex-smokers for less than 6 months with a smoking history of more than 10 pack years. 2. Other pulmonary co-morbidity (other than mild or moderate chronic airflow limitation). 3. Subjects having a co-existing illness that precludes them from the study. 4. Inability to give informed consent due to mental or legal reasons. 5. Pregnancy or lactation. 6. Known non-compliance with medications
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Leukemia Lymphoma Tumor Lysis Syndrome Hyperuricemia A diagnosis of hematologic malignancy Existing hyperuricemia or high risk of developing hyperuricemia of malignancy The treating clinician plans to treat the patient with rasburicase. A patient is only eligible for if the clinician has already decided to use rasburicase. Rasburicase should not be given in order to make a patient eligible for this non-therapeutic observational study No prior exposure to rasburicase or other urate oxidase A history of asthma or significant allergy  Wheezing or an active hypersensitivity reaction at entry Hypersensitivity to Aspergillus proteins
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Asthma, Bronchial Bronchial Asthma Diagnosis of asthma Patients treated with inhaled corticosteroid and long acting beta 2 agonist FEV1(forced expiratory volume in 1 second)>50% to 80%  Respiratory infection within 2weeks Asthma exacerbation within 6 weeks
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Asthma, Bronchial Bronchial Asthma Diagnosis of asthma Patients treated with inhaled corticosteroid FEV1 (forced expiratory volume in 1 second)>60% to 80%  Respiratory infection within 2 weeks Asthma exacerbation within 90 days
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 2.0-17.0,  Asthma, Bronchial age 2-17 years Clinical diagnosis of mild to moderate asthma as a second wheezing episode associated with signs of respiratory distress suggesting lower airway obstruction such as tachypnea and/or use of accessory muscles of respiration baseline Pulmonary Index Clinical Score (Appendix B) ≤ 11 out of 15 possible points as well as PRAM ≤ 8 out of 12 points Presenting to the Sick Kids Emergency Department Children capable of FEV1 measurement will have FEV1 more than 60% of the predicted value male or female Willing and able to provide informed consent (or informed consent by parents)  No previous history of wheezing or bronchodilator therapy. This population may eventually have diagnoses other than asthma or viral induced wheezing Patients who received more than a single dose of oral corticosteroids within 72 hours prior to arrival Patients receiving more than 500 mcg per day of fluticasone for more than 1 month or more than 250 mcg of fluticasone for more than 7 days prior to arrival Patients who have had more than 2 previous visits to the asthma clinic at SickKids Patients who received Montelukast within one week of arrival Critically ill patients requiring airway stabilization Patients with severe asthma, defined as PI 12 to 15 or PRAM 9 to 12 Co-existent co-morbidities such as chronic pulmonary disease and cardiac disease requiring pharmacotherapy, neurologic disease and immune disorders Previous admission to ICU for asthma More than 3 hospitalizations for asthma during the past 12 months
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Asthma Symptoms of asthma as defined by the American Thoracic Society (ATS) definition. This includes the following: 1. history of episodic shortness of breath (with or without associated wheezing) in association with reversible obstructive airways disease with at least a 20% decrement in FEV1 and FVC (from predicted values) that is documented at some time point by pulmonary function tests 2. an improvement in expiratory flow rates of at least 15% of predicted values after inhalation of a beta-2 selective bronchodilator medication or other previous treatment (e.g. corticosteroids) The diagnosis may also be confirmed by an abnormal bronchospastic response to methacholine or exercise as described by Cherniak FEV1 greater than or equal to 70% of predicted value at time of study entry Regular use of inhaled corticosteroids at time of study entry (at least 400 mcg of Beclomethasone or equivalent)  Used inhaled cromolyn (Intal) or nedocromil (Tilade) in the month prior to study entry History of severe asthma requiring intubation Any cardiopulmonary or neurologic abnormality with which the risk of performing the procedure would outweigh the potential benefits (other than asthma) Upper respiratory tract infection or clinical evidence of a sinus infection during the month preceding the test History of cigarette smoking within the 5 years prior to study entry or greater than 10 pack-years total Pregnant or refuses to undergo urine pregnancy testing if female of child-bearing age (women of childbearing potential will not be challenged [methacholine challenge] unless they have had a menstrual period in the last 10 days or a negative pregnancy test within 2 weeks or are practicing adequate contraception)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 8.0-18.0,  Asthma Children >8 years with severe asthma defined as: Taking at least 500mcg fluticasone propionate (or equivalent) per day, plus a long acting beta agonist plus a leukotriene antagonist or previous trial  Children taking steroid sparing agent (cyclosporin, azathioprine, methotrexate) Children with other major respiratory diagnoses such as bronchiectasis -
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 10.0-15.0,  Asthma Resident of Baltimore City Diagnosis of asthma or reactive airway disease Current emergency department visit or hospitalization for asthma Prescribed a daily asthma controller medication  Plans to move outside of the Baltimore City area within 1 year from study entry Current participation in another asthma education study Families unwilling or unable to participate Families who were enrolled and participated in the pilot study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-8.5,  Asthma Females between 5 and 7.5 years and male between 5 and 8.5 years of age with normal heights, a history of mild persistent asthma for at least 3 months prior to visit 1, a forced expiratory volume in one second (FEV1) of ³80% of predicted following at least a 4-hour albuterol withhold, and treated with non-corticosteroid asthma medications on an as-needed or daily basis, or with low doses of inhaled corticosteroids (ICSs) for at least one month prior to Visit 1. Subjects were to be no greater than Stage 1 in the Tanner classification of sexual maturity, and they had to be able to demonstrate effective use of the MDI devices and perform reproducible pulmonary function test  Subjects with a history of life-threatening asthma, severe respiratory impairment, history of abnormal growth, concurrent disease or condition which may substantially affect growth, previous requirement for daily or alternate day oral corticosteroids (OCS) treatment for ³60 days within the 2 years of Visit 3 and/or any use of OCS within 30 days prior to Visit 1 or during the run-in period, previous treatment with moderate or high doses of inhaled corticosteroid during the 30 days prior to Visit 1
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 2.0-10.0,  Asthma All patients must have a known history of asthma and present to the hospital/clinic with severe acute exacerbation. 2. Male or female patients 2 to 10 years of age. 3. Parents or legal guardians of patients must sign an Informed Consent Form prior to participation in the trial  Patients with known or suspected hypersensitivity to study drugs 2. Patients with medical condition that would contraindicate the use of beta2-adrenergic or anticholinergic medications 3. Patients with first wheezing episode only 4. Prior intubation for asthma for more than 24 hours 5. Patients who used ipratropium within six hours prior to consultation 6. Patients with concurrent stridor or possible presence of intra-thoracic foreign body 7. Patients with disease known to have chronic effect on respiratory function ( e.g., cystic fibrosis or cardiac disease) 8. Patients requiring immediate resuscitation or airway intervention 9. With psychiatric disease or psychosocial problems 10. Patients on other investigational drugs or have used any other investigational drugs within the past month